ALTAMIRA THERAPEUTICS LTD (CYTO)
Institutional ownership reported to the SEC as of Q3 2023, across 9 quarters.
8
Reporting holders
$217.2K
Reported value
0.0%
Held as options
+3
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $202.7K | 829,000 | 0.00% | new | NEW |
| CITADEL ADVISORS LLC | $9.4K | 39,165 | 0.00% | 2q | -46.3%-$8.1K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.5K | 10,185 | 0.00% | new | NEW |
| XTX Topco Ltd | $2.4K | 10,131 | 0.00% | new | NEW |
| MORGAN STANLEY | $122 | 500 | 0.00% | 4q | HELD |
| GROUP ONE TRADING, L.P. | $72 | 298 | 0.00% | 2q | HELD |
| WELLS FARGO & COMPANY/MN | $6 | 25 | 0.00% | 4q | HELD |
| Stonebridge Capital Advisors LLC | $1 | 5 | 0.00% | 4q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q3 2023 | 8 | $217.2K | 889,309 | 3 | 0 | 1 | 0.0% |
| Q2 2023 | 5 | $47.3K | 73,759 | 2 | 0 | 1 | 0.0% |
| Q1 2023 | 6 | $7.3K | 5,676 | 2 | 0 | 2 | 0.0% |
| Q4 2022 | 6 | $83.5K | 7,120 | 6 | 0 | 0 | 58.7% |
| Q3 2022 | 10 | $130.0K | 414,323 | 4 | 2 | 2 | 8.5% |
| Q2 2022 | 11 | $161.0K | 294,634 | 3 | 4 | 2 | 11.8% |
| Q1 2022 | 14 | $746.0K | 554,413 | 3 | 4 | 2 | 18.6% |
| Q4 2021 | 16 | $1.5M | 629,910 | 3 | 5 | 6 | 24.6% |
| Q3 2021 | 15 | $1.4M | 669,284 | 15 | 0 | 0 | 2.7% |